FLT4 and breast neoplasm: In line with this notion, a recent study on a breast tumor-bearing mouse model showed that metronomic PTX treatment suppresses VEGFR-2 expression, tumor angiogenesis, and lymphatic vessel formation, although the authors did not examine the expression levels of VEGFR-3, a lymphangiogenic receptor8.